Diagnosis: NSCLC
Treatment: Guardant360
The Guardant360 was not medically necessary.

There is no evidence to support Guardant 360 testing in a patient with NSCLC who has already undergone FoundationOne one testing and been found to have an ALK mutation. The NCCN only recognizes molecular panel testing at initial diagnosis. They do not recommend multiple panel testing or repeat panel testing in patients with NSCLC.

The SHIVA study has shown that the use of NGS (next generation sequencing) panel testing in advanced cancer patients does not improve clinical outcomes.